Effect of Omega3 in depressio
Phase 3
- Conditions
- Major depressive disorder.Major depressive disorder, recurrent severe without psychotic featuresF33.2
- Registration Number
- IRCT20201125049487N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patient with major depressive disorder who had been to the psychiatric clinic of Golestan.
Age witbeen 18-65 years
Exclusion Criteria
Bipolar disorder and other psychiatric disorders
Drug or alcohol consumption during the research, dependence or history of drug or alcohol in 6 recent months,
History of allergy to serotonin reuptake inhibitors or omega- 3fatty acids
History of seizure
Pregnancy
Active suicidal thoughts and homicide
Use of anticoagulants and medications that interfere with omega- 3 intake (such as anti-platelet drugs such as aspirin and enoxaparin and heparin and warfarin)
chronic physical disease ( blood pressure, diabetes, heart disease, liver and kidney disease )
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Depression values in beck test. Timepoint: From the start of treatment and week 2,4,6,8. Method of measurement: Beck test.
- Secondary Outcome Measures
Name Time Method Dose of SSRI. Timepoint: At the beginning of treatment and week 2,4,6,8 after tratment started. Method of measurement: Evaluation of drug used based of patient file.